Recruitment Completed In Ofatumumab CLL Front Line Study

Summary:  Genmab has completed recruitment of patients in the Phase II study of 
ofatumumab in combination with fludarabine and cyclophosphamide to treat front  
line CLL.                                                                       

Copenhagen, Denmark; July 9, 2008 - Genmab A/S (OMX: GEN) announced today it has
completed recruitment of 56 patients in the Phase II study of ofatumumab        
(HuMax-CD20 (R)) in combination with fludarabine and cyclophosphamide (FC) to 
treat chronic lymphocytic leukemia (CLL) in previously untreated patients.      

“We are pleased to complete patient enrollment in the first front line study of 
ofatumumab and hope to see a positive outcome for the CLL patients in this      
trial,” said Lisa N. Drakeman, Ph.D., Chief Executive Officer of Genmab.        

Ofatumumab is an investigational fully human, next generation monoclonal        
antibody that targets a unique epitope of the CD20 molecule on the surface of   
B-cells. Other anti-CD20 antibodies currently available or in development bind  
to a different epitope on the CD20 molecule. Ofatumumab is being developed to   
treat CLL, follicular non-Hodgkin's lymphoma, diffuse large B-cell lymphoma,    
rheumatoid arthritis and relapsing remitting multiple sclerosis under a         
co-development and commercialization agreement between Genmab and               
GlaxoSmithKline.  It is not yet approved in any country.                        

About the trial                                                                 
Patients in this open label study will be randomized into two treatment groups  
of 28 patients each.  Each patient will receive 6 monthly infusions of either   
500 or 1000 mg of ofatumumab in combination with FC.  Disease status will be    
measured every 4 weeks until week 24 according to National Cancer Institute     
Working Group Guidelines and every 3 months thereafter until disease progression
or 24 months.  Patients not having progressed on their disease at 24 months will
be followed for disease progression at 6 month intervals until 48 months.       

The objective of the study is to determine the efficacy of ofatumumab in        
combination with FC in previously untreated CLL patients.  The primary endpoint 
is complete remission measured at any time during the treatment period.         

About Genmab A/S                                                                
Genmab is a leading international biotechnology company focused on developing   
fully human antibody therapeutics for unmet medical needs.  Using cutting-edge  
antibody technology, Genmab's world class discovery, development and            
manufacturing teams have created and developed an extensive pipeline of products
for potential treatment of a variety of diseases including cancer and autoimmune
disorders.  As Genmab advances towards a commercial future, we remain committed 
to our primary goal of improving the lives of patients who are in urgent need of
new treatment options.  For more information on Genmab's products and           
technology, visit www.genmab.com.                                               

This press release contains forward looking statements. The words “believe”,    
“expect”, “anticipate”, “intend” and “plan” and similar expressions identify    
forward looking statements. Actual results or performance may differ materially 
from any future results or performance expressed or implied by such statements. 
The important factors that could cause our actual results or performance to     
differ materially include, among others, risks associated with product discovery
and development, uncertainties related to the outcome and conduct of clinical   
trials including unforeseen safety issues, uncertainties related to product     
manufacturing, the lack of market acceptance of our products, our inability to  
manage growth, the competitive environment in relation to our business area and 
markets, our inability to attract and retain suitably qualified personnel, the  
unenforceability or lack of protection of our patents and proprietary rights,   
our relationships with affiliated entities, changes and developments in         
technology which may render our products obsolete, and other factors. Genmab is 
not under an obligation to up-date statements regarding the future following the
publication of this release; nor to confirm such statements in relation to      
actual results, unless this is required by law.                                 

Genmab(R); the Y-shaped Genmab logo(R); HuMax(R); HuMax-CD4(R); HuMax-CD20(R);  
HuMax-EGFr(TM); HuMax-IL8(TM); HuMax-TAC(TM); HuMax-HepC(TM); HuMax-CD38(TM);   
HuMax-CD32b(TM) and UniBody(R) are all trademarks of Genmab A/S.                

Contact: Helle Husted, Sr. Director, Investor Relations, T: +45 33 44 77 30, E: 
hth@genmab.com                                                                  
                                                                                
Stock Exchange Release no. 33/2008                                              

###